Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan CDMO Market Up Only Slightly in 2023 as COVID Windfall Falters: Report
August 7, 2024
- LEO Pharma Wins Approval for Pen Version of Adtralza
August 6, 2024
- Shionogi’s Antibiotic Cefiderocol Accepted for Review in China
August 6, 2024
- Japan Major Pharmas Endure Market Crash, but Biotechs Take a Hit
August 6, 2024
- Kyowa Kirin’s H1 Sales up 16.9% on North American Biz, Strategic Brands
August 5, 2024
- Kyowa Kirin Not Ruling Out Small Molecule Drug Research: CMO
August 5, 2024
- Otsuka Wants to Make Jnana Cornerstone of Future Drug Discovery: CEO
August 5, 2024
- Takeda Announces Reorganization, Buyout Program in Japan
August 5, 2024
- Daiichi Sankyo Kicks Off Global PIII Study for B7-H3-Directed ADC
August 5, 2024
- Takeda to Prune 1,000 Jobs in US
August 5, 2024
- Alecensa Nabs Additional Nod in Earlier NSCLC Setting: Chugai
August 5, 2024
- Eisai Stands Firmly Behind Leqembi Profile despite EU Rejection
August 5, 2024
- Kyowa Kirin Pulls Plug on Stand-Alone Sales in China, Retools Asian Strategy
August 2, 2024
- Otsuka Picks Up Jnana Therapeutics for US$800 Million
August 2, 2024
- Kyowa Kirin to Offer Buyout Packages amid Research Rejig
August 2, 2024
- Otsuka’s H1 Pharma Sales Soar 18% on Rexulti, Lonsurf
August 2, 2024
- Ono Inks Fresh GPCR Antibody Pact with Monash University
August 2, 2024
- Mitsubishi Tanabe’s Buyout Program Has No Bearing on Potential Divestment: EVP
August 2, 2024
- Xtandi’s Global Sales Surge Nearly 30% in April-June: Astellas
August 2, 2024
- Leqembi’s April-June Sales Up 2.2-Fold from Prior Quarter: Eisai
August 2, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…